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CASE PRESENTATION
A 52-year-old African woman, living in France since
5 years, presented with dyspnea and pyrexia. She had a
1-month history of sore throat treated with amoxicillin,
migratory polyarthralgia, drenching night sweats, and an
evanescent, maculo-papular, non-pruritic rash mainly on
her limbs lasting less than 1 week at a time. She denied
smoking, alcohol abuse, and illicit drugs use. She had no
risk factors for HIV. Examination on admission revealed a
temperature of 39.51C, tachycardia, a blood pressure of
120/70 mm Hg, pallor, jaundice, splenomegaly, and
bilateral inflammation of knee and ankle joints with
synovitis, and severe tenderness of the wrist with signs of
fluid overload. There was no sign of meningeal irritation,
no focal neurological deficit and normal fundus
examination. There were fine crepitations involving the
left lung base. Heart sounds were normal on auscultation
with no murmur. She was admitted for analgesia and
antibiotics pending the results of infective screens and
blood tests. Peripheral smear showed no malarial parasite.
Her coagulation profile was normal and there was no
biochemical evidence of hemolysis. Biochemistry values
are summarized in Table 1. Human Immunodeficiency
Virus serology, plasma HIV viral load, and p24
determination were negative. Serologies for, hepatitis B
and C, Parvovirus B19, cytomegalovirus, Epstein–Barr
virus, leptospira, bartonella, rickettsia, chlamydia,
mycoplasma pneumoniae, legionella, Widal test, rapid
malaria test, toxoplasma, and syphilis were all negative.
Brucella agglutination test and leishmania
leukococentration were also negative. Hemoglobin
electrophoresis ruled out sickle cell disease. Laboratory
evaluation for systemic or malignant diseases, including
rheumatoid factor, antibodies to double-stranded
deoxyribonucleic acid, smooth muscle cell, liver/kidney
microsomal, mitochondrial, anti-cardiolipin, anti-Scl,
antineutrophilic cytoplasmic antibody, anti-Ro, anti-La,
anti-SM, anti-ribonucleoprotein, anti-Jo-1, and
anti-glomerular basement membrane antibodies were all
negative. Immunological parameters were non-
contributory with polyclonal hypergammaglobulinemia,
normal immunoglobulin (Ig) A, IgM, complement levels,
and negative cryoglobulinemia. Chest X-ray was normal.
Renal ultrasound showed enlarged, swollen kidneys
measuring 12.6 cm in length each. Total body computed
tomography revealed splenomegaly, with the rest of the
scan being unremarkable. This association between a
nephrotic syndrome, fever, cutaneous lesions, pharyngitis
and arthralgias suggested the diagnoses of either
postinfectious or membranoproliferative
glomerulonephritis. A first trans-jugular kidney biopsy was
then performed (Figure 1).
Trans-thoracic echocardiography suspected the
presence of mitral valve endocarditis. Despite empirical
treatment with Cefotaxim and gentamicin, she did not
improve. The maculo-papular rash on her limbs persisted
alongside with high fevers. Bone marrow biopsy and
aspiration revealed moderately hyper-cellular marrow
with trilineage maturation, and increased number of
macrophages, however, without hemophagocytosis.
Repeated serologies and cultures were negative. A second
trans-oesophageal echocardiography revealed that the
systolic function and chamber sizes were normal; there
was no valvular dysfunction, evidence of vegetations, nor
pericardial effusion. Her renal function worsened
(creatinine peaking at 600mmol/l 1 week later) and
hemodialysis became necessary. Suspecting a rapidly
progressive glomerulonephritis, of postinfectious or
vasculitic nature, a second trans-jugular kidney biopsy was
performed (Figures 2 and 3).
At this stage we were faced with a severely ill 52-year-old
African woman presenting with pyrexia of unknown origin,
migratory polyarthopathy, fleeting maculopapular rash,
pancytopenia, and rapidly progressive glomerulonephritis
with renal failure requiring renal support.
KIDNEY BIOPSY FINDINGS
The two renal biopsies were similar and consistent with
collapsing glomerulopathy (CG) (Figure 1).
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For each, two cores of renal cortex were examined
histologically after routine processing and staining. At least
25 glomeruli were sampled, of which six were sclerotic. One
contained a segmental sclerosis and seven were essentially
normal. The remaining 11 (45%) showed tuft collapse in
association with prominence of Bowman’s space. There was
no necrosis, crescents, nor proliferative features within the
glomeruli. Immunohistochemistry revealed a small amount
of trapped mesangial IgM and complement; IgG and IgA
were completely negative. Congo red staining was also
negative. Acutely damaged tubules with dilatation, flattened
epithelial cells, and cytoplasmic vacuolation were seen.
Moderate scarring with a patchy mixed inflammatory cell
infiltrate was also present, occasionally with intra-tubular
infiltration by polymorphs. The vessels were essentially
normal. Electron microscopy was not performed.
PATHOLOGICAL DIAGNOSIS
CG in the setting of febrile pancytopenia and arthritis.
CLINICAL FOLLOW-UP
The patient was diagnosed with adult onset Still’s disease
(AOSD) because she met the Yamaguchi et al.,1 Cush et al.,2
and Fautrel et al.3 criteria for this diagnosis (Table 2).
Glycosylated ferritin was at 52% in our patient. This marker
is considered a better diagnostic tool for AOSD than total
serum ferritin.3 It may, however, also be observed in
macrophage activation syndrome (MAS) of other origins
and so cannot be distinctive.4
She was treated with intravenous immune globulin (IVIG)
(total dose 2 g/kg given over 4 days) in association with
methylprednisolone pulses 15 mg/kg daily for 3 days,
followed by 1 mg/kg daily prednisone with partial sympto-
matic improvement. Fevers ceased the day after initiation of
Table 1 | Biochemistry values at baseline and after 2 weeks
follow-up
Laboratory tests At admission Two weeks later
WBC count ( 103/ml) 13.2 15.5
Neutrophil count
( 103/ml)
8.5 10.0
Hemoglobin (g/dl) 8.2 7.0
Platelet count
( 103/ml)
80.000 60.000
Peripheral smear Microcytic hypochromic, anisopoikilocytosis,
and polychromatic cells, without schizocytes
Haptoglobin (g/l) 2.50 2.30
Bilirubin (mmol/l) 20 77
ALT (IU/l) 25 78
Urea (mmol/l) 7.6
Creatinine (mmol/l) 150 550
Albumin (g/l) 27 21
LDH (IU/l) 1269 1065
CRP (mg/l) 150 200
Ferritin (ng/ml) 2570 4000
Triglyceride (mmol/l) 10 10
Dipstick urinalysis 4+ protein without leukocyte or red blood cells
Urine microscopy RBCs less than 1000/ml WBCs less than 1000/ml
(less than 1 HPF for both), no casts
24 h urinary
protein (g)
5.2 then 10 without urinary Bence Jones protein
ALT, alanine aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase;
RBCs, red blood cells; WBC, white blood cell.
Figure 1 | The glomerular tuft is segmentally collapsed with
podocyte hypertrophy associated with microcystic dilatation of
tubules and mild lymphocytic interstitial infiltrate consistent
with CG. Masson’s trichrome, original magnification  200.
Figure 2 | The glomerular tuft is segmentally collapsed with
podocyte hypertrophy associated with microcystic dilatation
of tubules and mild lymphocytic interstitial infiltrate consistent
with CG. Masson’s trichrome, original magnification  400.
Figure 3 | Glomerular basement membrane collapse with
hypertrophy of the overlying podocytes. Jones methenamine
silver; original magnification  200.
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pulse methylprednisolone. However, as the steroids were
given orally, her symptoms recurred within 3 days and she
developed hepatitis, which may have been triggered by a
medication or by an acute infection. All blood cultures
obtained throughout the course of her illness were sterile.
The patient have a global T-cell lymphopenia (443/mm3) and
the analysis of flow cytometry show that during follow-up,
78–90% of monocytes–macrophages were activated (expres-
sion HLA DR).
At that point, it was concluded that the addition of
another agent to control disease activity was indicated. The
recently reported use of anticytokine or anti-CD20 agents in
refractory cases has opened new horizons in the treatment of
AOSD. Amid these newly added options we have chosen
Anakinra due to its better side effects profile. Anakinra
(Kineret; Amgen, Inc., Thousand Oaks, CA, USA) 100 mg
subcutaneously twice weekly coordinated with the dialysis
schedule was initiated in association with dexamethasone
pulse 40 mg daily for 3 days, resulting in remission of the
rheumatological condition closely paralleled by remission of
proteinuria and renal function, thereby strongly suggesting a
causative link between AOSD and CG. Anakinra was well
tolerated and without burning at the injection sites.
Marked improvement in renal parameters has been noted,
10 days after the combined therapy. This improvement was
manifested by the recovery of normal diuresis and dialysis
withdrawal.
Meanwhile, her renal function remained stable and she
was free of dialysis, with serum creatinine within the range of
160–180 mmol/l and proteinuria of 2þ . She was prescribed
prednisone 1 mg/kg daily in four split doses. The delay
between institution of treatment and remission and dialysis
stopping was 2 months.
DISCUSSION
We report a rare case of AOSD-related MAS and CG which
dramatically improved with interleukin-R (IL-R) antagonist
and corticosteroid combination.
Nephrotic syndrome associated to a febrile pharyngitis
raises first the possibility of a postinfectious GN. However,
the presence of CG on biopsy alongside with the clear
cutaneous and articular manifestations were clues to a
primary joint disease such as AOSD.
Only 16 cases of AOSD-related MAS have been reported in
the English language literature.5 On the other hand,
Albaqumi et al.6 in their recent and excellent review on
CG, mentioned only two and five cases related to AOSD7,8
and MAS,9 respectively. Table 3 summarize characteristics of
the three AOSD-related CG African patients’ including ours.
Collapsing glomerulopathy
CG is a distinct pattern of renal injury characterized by global
or segmental collapse of the glomerular tuft, visceral
hypertrophy, and hyperplasia accompanied with varying
degrees of tubulointerstitial injury. It is frequently and
primarily seen in patients with HIV infection10 and recently
has been increasingly recognized with non-HIV medical
conditions10,11 (Table 4). However, CG was rarely recognized
to be MAS- or AOSD related. Clinically, CG is typically
characterized by more or less abrupt onset of nephrotic-range
proteinuria with rapid progression to end-stage renal failure.
Laurinavicius et al.10 reported nephrotic-range proteinuria at
Table 2 | AOSD diagnostic criteria
Yamaguchi et al. Cush et al. Fautrel et al.
Major
2 points
Arthralgia42 weeks* Quotidian fever4391* Spiking fever X 391*
Fever4391, intermittentX1 week* Evanescent rash* Arthralgia*
Typical rash* WBC412 0*+ESR440 mm/1st h Transient erythema*
WBC410 000 (480% granulocytes)* Negative RF and ANA* Pharyngitis*
Carpal ankylosis PMNX80%*
Glycosylated ferritinp20%
Minor
1 point
Sore throat* Onset age o32 years Maculopapular rash*
Lymphadenopathy and/or splenomegaly* Arthritis* LeukocytesX10 109/l*
LFT abnormal Prodromal sore throat*
Negative ANA and RF* RES involvement or abnormal LFTs
Serositis*
Cervical or tarsal ankylosis
Diagnostic
Five criteria (at least two major) Probable AOSD: 10 points with 12 weeks’
observation Definite AOSD; 10 points with 6
months’ observation
Four major criteria or three major+two minor
ANA, anti-nuclear antibodies; AOSD, adult onset Still’s disease; ESR, erythrocyte sedimentation rate; LFT, liver function test; PMN: polymorphonuclear cells;
RES: reticuloendothelial system; Rh, rheumatoid factor; WBC, white blood cell.
*Our patients.
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the time of initial presentation in 89% of patients with a
median renal survival of 13–16 months. Variable outcome
with respect to renal survival has been observed, with
regimens consisting of steroids, with or without cyclopho-
sphamide or cyclosporin.10,11 Valeri et al.11 noted a 14% total
remission rate among the CG patients, including few
attaining spontaneous remission without any therapy.
Targeting the AOSD with subsequent improvement of the
renal parameters indicated that CG was not an epiphen-
omenon.
Amid the multiple etiologies of CG, our patient presented
two quite rare causes.
Macrophage activating syndrome
MAS or hemophagocytic lymphohistiocytosis is a rare and
potentially fatal disease of normal but overactive histiocytes.
It is of two types – primary MAS as observed in various
genetic diseases affecting the immune system and secondary
(or acquired) MAS that occurs after strong immunologic
activation – systemic infection (virus, bacteria, and proto-
zoa), autoimmune disorders, or underlying malignancy. The
clinical entity has to be suspected when patients present with
fever unresponsive to antibiotics, general fatigue, falling
erythrocyte sedimentation rate, pancytopenia of unknown
origin and liver dysfunction with low fibrinogen levels,
Table 3 | Clinical and laboratory data for three patients with CG and AOSD
Characteristics
Adult onset Still disease
Literature
Our case
Patients number age/gender/
race No. 1 46/Woman/African No. 2 32/Man/African No. 3 52/Woman/African
Clinical findings and biological parameters
Fever 39.51C 401C 39.51C
Arthritis/synovitis +/+ +/ +/+
Hepato-splenomegaly +  +
Adenopathy + + 
Skin rash + + +
Hemoglobin (g/dl) 7.8 7.7 7.2
White blood cell count (103/ml) 13.2 17.3 17.5
Neutrophils count (%) 74.4 14.4
Platelet count (109/l) Not available 444 70
LDH (IU/l) 1,269 1065 1065
Ferritin (ng/ml) 4970 38 691 4000
Renal abnormalities
Serum creatinine (mmol/l) 220 515 180
Proteinuria (g/24 h) 5.1 7.2 3.5
Serum albumin (g/l) 31 11 27
Microhematuria   
Kidney size Enlarged (12.6 cm) Not available Normal (11 cm)
Kidney pathology
No. of collapsed glomeruli 11/25 Several 11
No. of sclerotic glomeruli 6/25 Not available 6
Tubules Dilatation with prominent
luminal proteinaceous casts
Microcyst tubular dilatation,
flattened epithelial cells, and
cytoplasmic vacuolisation
Tubular dilatation, flattened
epithelial cells, and cytoplasmic
vacuolisation
Interstitium Moderate scarring with a patchy
mixed inflammatory cell infiltrate
Not available Patchy inflammatory infiltrate
Vessels Normal Not available Normal
Immunofluorescence Negative Negative Negative
Electron microscopy No electron-dense deposits, no
fibrillary or light-chain material,
and no tubulo-reticular inclusion
bodies within endothelial cells
Swollen epithelial cells with
partial effacement of the foot
processes. No electron-dense
deposit
Not performed
Treatment and outcome
Steroids Oral steroid No Pulse of methyprednisolone, then
oral steroid
Cytotoxic agents No MMF 1 g daily Negative
Iv Ig No 0.4 g/kg daily for 5 days 0.5 g/kg daily for 4 days
IL-1-ra No No Anakinra
Outcome Well 3 years later Well 15 months after Well 2 months after
Dialysis No No Transient
IL-1-ra, interleukin-1-receptor antagonist; Iv Ig, intravenous immunoglobulin; LDH, lactate dehydrogenase.
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marked hypertriglyceridemia, and elevated ferritin, lympha-
denopathy, and sometimes skin rash, lung infiltration.12
There are few reports of renal involvement in MAS. Acute
renal failure is thought to be the most consistent feature12
and is considered by some authors as a strong prognostic
factor.13 In one series of 57 patients with reactive MAS, 62%
had evidence of renal impairment with 17% requiring
dialysis.14 Moreover, in a multicentric retrospective study
which included 11 patients, acute renal failure was associated
with nephrotic syndrome in 90.9% and death occurred in
seven cases.9 However, Ramanan et al.15 describe three
children with systemic onset juvenile rheumatoid arthritis
who had glomerular involvement complicating MAS with a
favorable outcome. Nonetheless, biopsy-proven renal invol-
vement has remained poorly documented. Thaunat et al.9
clarified the clinicopathological profile of patients with
nephrotic syndrome occurring during MAS in 11 HIV-
negative black African patients. Renal pathological findings
included CG (45.5%), minimal change glomerulopathy
(36.3%), and thrombotic-microangiopathy (18.2%). Treat-
ment of MAS is not uniform. In the absence of prospective
controlled trials in MAS, corticosteroids, cyclosporin A,
etoposide, anti-tumor necrosis factor-a drugs, and plasma-
pheresis are administered with varied success.
Adult-onset Still disease
Adult-onset Still disease is a systemic inflammatory condition
of unknown etiology. In 1971, Bywaters16 first described this
new disease entity that he named adult Still’s disease. It
involved adult patients who did not meet the criteria for
classic rheumatoid arthritis but displayed features similar to
those described in pediatric Still’s disease. However, the
earliest documentation of an adult with signs and symptoms
of AOSD was published in 1896.17 Its prevalence has been
estimated to be lower than one case per 100 000 persons.18 In
clinical practice, AOSD is usually considered a diagnosis by
exclusion particularly when it presents as fever of unknown
origin. Owing to the ambiguity of its definition and the lack
of serologic markers, several criteria have been proposed for
AOSD in the literature.1–3,19 Kidney involvement has been
rarely reported in AOSD. Mesangial glomerulonephritis,
disseminated intravascular coagulation, thrombocytopenic
purpura,20 interstitial nephritis,21 subacute glomerulitis,22
and renal amyloidosis leading to renal insufficiency have been
reported to occur in patients with AOSD. Kumar et al.8
reported a 46-year-old Afro-Carribean woman who presented
concomitant occurrence of AOSD and CG. The patient was
treated with steroids, resulting in remission of the rheuma-
tological condition closely paralleled by remission of
proteinuria and renal function, thereby strongly suggesting
a causative link between AOSD disease and CG. Bennett
et al.7 reported severe AOSD and CG improved successfully
with intravenous immune globulin and mycophenolate
mofetil in a 32-year-old African man.
The pathogenesis of AOSD is poorly understood and the
treatment empirical. It essentially involves the use of
nonsteroidal anti-inflammatory drugs, steroids, immunosup-
pressants, and, currently, biologic agents to control fever,
arthritis, and systemic disease. Elevated levels of IL-1 have
been implicated in the pathogenesis of AOSD and IL-1
blockers have emerged as possible therapeutic options. Aelion
et al.23 reported the successful outcome of daily subcutaneous
anakinra (100 mg), a recombinant IL-1 receptor antagonist
(IL1-rA), in two patients with persistent AOSD. The first
patient achieved complete clinical remission on anakinra
alone within days, paralleled by normalized laboratory
values, while the other patient was weaned off corticosteroids
within weeks and remained in remission on anakinra and
MTX.23 In another series of three AOSD patients, addition of
anakinra to a corticosteroid regimen resulted in clinical
improvement within days and, subsequently, tapering of the
corticosteroid dosage.24 A recent study of four patients also
demonstrated the efficacy of anakinra in refractory AOSD.
Remission was sustained, and prednisone eventually discon-
tinued, in three of the four patients. Convincingly, when
anakinra was withdrawn in two patients, their disease
relapsed with fever, arthritis, rash, and elevation of laboratory
markers within days. Both patients rapidly responded to re-
institution of IL-rA.25
CG must be suspected in AOSD and/or MAS with
unexplained renal insufficiency or proteinuria. In this
Table 4 | Secondary causes of collapsing glomerulopathy
Infections
HIV
Parvovirus B19
Others (HCV, CMV, leishmaniasis, filariosis, tuberculosis, etc)
Drugs and toxic
Pamidronate
Interferon
Heroin
Post transplantation
De novo
Recurrent
Others (thrombotic microangiopathy, acute vascular rejection, etc)
Autoimmune disorders
Systemic lupus erythematous-like disease
Adult Still disease
Others (mixed connective tissue disease, cerebral arteritis, etc)
Inflammatory disease
Weber-Christian disease
Malignancies
Multiple myeloma
Acute monoblastic leukemia
Macrophage activation syndrome
Genetic disorders
Mitochondrial cytopathy
Action myoclonus-renal failure syndrome
Homozygous sickle cell anemia
CMV, cytomegalovirus; HCV, hepatitis C virus.
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situation, renal biopsy is necessary to establish a definitive
diagnosis. Historically, treatment consisted of nonsteroidal
anti-inflammatory drugs, often in combination with
low-dose corticosteroids. Immunosuppressants (mainly
methotrexate, but also intramuscular gold, azathioprine,
cyclosporine A, leflunomide, and cyclophosphamide) and
intravenous g-globulin are efficacious and have been used as
steroid-sparing drugs. The recently reported use of antic-
ytokine and anti-CD20 agents in refractory cases has opened
new horizons in the treatment of AOSD and provided
important clues as to its pathophysiology.
Anakinra in addition to steroids looks like a promising
combination for the treatment of this condition as it was the
case in our patient.
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